Imaging of Tumour Microenvironment in Patients With Oropharyngeal Head and Neck Squamous Cell Carcinoma Using RGD PET/CT Imaging (PIVOT)
2020年1月6日 更新者:Radboud University Medical Center
Known risk factors inducing squamous cell carcinomas of the head and neck are tabacco and alcohol intake.
However, the incidence of human papillomavirus (HPV) related oropharyngeal carcinomas is increasing.
It is known that HPV+ and HPV- tumors have a different reaction to (chemo)radiotherapy.
The exact mechanisms underlying these differences is not yet known but might be caused by changes in vascularity.
Therefore the vasculature is imaged with the help of a study specific Gallium-68-DOTA-(RGD)2 PET/CT scan and a CT perfusion scan.
研究概览
详细说明
The incidence of Human Papilloma Virus positive (HPV+) oropharyngeal Head and Neck Squamous Cell Carcinoma (HNSCC) is rising and it has become evident that this type of cancer represents a subgroup of HNSCC that is characterized by a more favourable prognosis, mediated by a distinct tumour microenvironment, compared to patients with HPV negative (HPV-) tumours.
However, the exact mechanisms underlying this improved treatment outcome and the potential role of the tumour microenvironment are not fully understood yet.
Imaging of αvβ3 integrin expression will obtain more insight in the differences in tumour microenvironment between HPV+ and HPV- oropharyngeal HNSCC.
CT perfusion provides additional characterisation of this tumour microenvironment.
Therefore, these techniques may have the potential to predict response to treatment and might possibly steer treatment decisions in future clinical trials.
研究类型
介入性
注册 (预期的)
20
阶段
- 阶段2
联系人和位置
本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。
学习联系方式
- 姓名:E Aarntzen, MD, PhD
- 电话号码:+31243614048
- 邮箱:Erik.Aarntzen@radboudumc.nl
研究联系人备份
- 姓名:D Lobeek
- 电话号码:+31243614048
- 邮箱:Erik.Aarntzen@radboudumc.nl
学习地点
-
-
Gelderland
-
Nijmegen、Gelderland、荷兰
- 招聘中
- Radboudumc
-
-
参与标准
研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。
资格标准
适合学习的年龄
18年 及以上 (成人、年长者)
接受健康志愿者
不
有资格学习的性别
全部
描述
Inclusion Criteria:
- Proven squamous cell carcinoma of the oropharynx
- p-16 immunohistochemistry analysis
- Tumour lesion of at least 1.0 cm in diameter
- Planned chemoradiotherapy as primary treatment
- Ability to provide written informed consent
Exclusion Criteria:
- Contra-indications for PET
- Contra-indications for administration of iodine-containing contrast agents
- Other serious illness that can affect the scans
学习计划
本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。
研究是如何设计的?
设计细节
- 主要用途:其他
- 分配:非随机化
- 介入模型:并行分配
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
有源比较器:HPV Negative tumours
Patients will receive four scans.
|
Patients will receive an RGD PET/CT and a CT perfusion scan prior to treatment and during chemoradiotherapy
其他名称:
|
|
有源比较器:HPV positive tumours
Patients will receive four scans.
|
Patients will receive an RGD PET/CT and a CT perfusion scan prior to treatment and during chemoradiotherapy
其他名称:
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Differences in RGD-tracer uptake between HPV positive and negative tumours
大体时间:1 month
|
standardized uptake values (SUV) of Ga68-RGD
|
1 month
|
|
Differences in RGD-tracer uptake between the pre- and per-treatment scan
大体时间:1 month
|
standardized uptake values (SUV) of Ga68-RGD
|
1 month
|
|
Differences in CT perfusion flow parameters between HPV positive and negative tumours
大体时间:1 month
|
Determining the blood flow using ROIs of the tumour drawn on the contrast enhanced CT
|
1 month
|
|
Differences in CT perfusion parameters between HPV positive and negative tumours
大体时间:1 month
|
Determining the blood volume using ROIs of the tumour drawn on the contrast enhanced CT
|
1 month
|
|
Differences in CT perfusion flow parameters between the pre- and per-treatment scan
大体时间:1 month
|
Determining the blood flow using ROIs of the tumour drawn on the contrast enhanced CT
|
1 month
|
|
Differences in CT perfusion parameters between the pre- and per-treatment scan
大体时间:1 month
|
Determining the blood volume using ROIs of the tumour drawn on the contrast enhanced CT
|
1 month
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Differences in RGD-tracer uptake between patients with locoregional control or recurrence within one year
大体时间:1 year
|
standardized uptake values (SUV) of Ga68-RGD
|
1 year
|
|
Differences in CT perfusion flow parameters between patients with locoregional control or recurrence within one year
大体时间:1 year
|
Determining the blood flow using ROIs of the tumour drawn on the contrast enhanced CT
|
1 year
|
|
Differences in CT perfusion parameters between patients with locoregional control or recurrence within one year
大体时间:1 year
|
Determining the blood volume using ROIs of the tumour drawn on the contrast enhanced CT
|
1 year
|
合作者和调查者
在这里您可以找到参与这项研究的人员和组织。
研究记录日期
这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。
研究主要日期
学习开始 (实际的)
2019年11月22日
初级完成 (预期的)
2022年9月1日
研究完成 (预期的)
2023年9月1日
研究注册日期
首次提交
2019年11月20日
首先提交符合 QC 标准的
2020年1月6日
首次发布 (实际的)
2020年1月10日
研究记录更新
最后更新发布 (实际的)
2020年1月10日
上次提交的符合 QC 标准的更新
2020年1月6日
最后验证
2019年11月1日
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.